Study of the Utility of the BOMET-QOL Questionnaire Patients With Breast Cancer and Bone Metastasis
NCT ID: NCT03847220
Last Updated: 2023-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
241 participants
OBSERVATIONAL
2007-10-23
2012-07-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Imaging Evaluation of the Therapeutic Response of Breast Cancer Bone Metastasis (EMOS)
NCT02900118
Real World Study of Bone Metastases in Patients with Advanced Breast Cancer
NCT06873997
SBRT for Breast Cancer Oligometastases
NCT04424732
A Study for Dynamic Prediction Model of Breast Cancer Bone Metastases
NCT06544668
Clinical, Histological and In-depth Molecular Characterization as Well as Experimental Models of Liver Metastasis From Patients With Breast Cancer in Order to Identify New Potential Treatment Avenues.
NCT05720676
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inclusion criteria:
* Patient over 18 years of age.
* Patient diagnosed with breast cancer (BC) and bone metastases (BM).
* Patient who has granted informed consent in writing to participate in the study.
* Patient capable of understanding and completing the questionnaires.
Exclusion criteria:
* Patient with another type of disease that, in the investigator's opinion, could mask the study results.
* Patients with a life expectancy of less than 8 months.
* Patient who is participating in a clinical trial with an unregistered drug at the start of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BOMET-QoL questionnaire
study to evaluate the utility of the BOMET-QoL questionnaire in patients with BC and BM
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient diagnosed with BC and BM.
* Patient who has granted informed consent in writing to participate in the study.
* Patient capable of understanding and completing the questionnaires
Exclusion Criteria
* Patients with a life expectancy of less than 8 months.
* Patient who is participating in a clinical trial with an unregistered drug at the start of the study.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Spanish Breast Cancer Research Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario Virgen Del Rocío
Seville, Andalusia, Spain
Hospital General de Guadalajara
Guadalajara, Castille-La Mancha, Spain
ICO Badalona Hospital Universitari Germans Trias I Pujol
Badalona, Catalonia, Spain
Hospital Universitari Clinic I Provincial
Barcelona, Catalonia, Spain
Hospital Santa Creu I Sant Pau
Barcelona, Catalonia, Spain
Hospital Mutua de Terrassa
Barcelona, Catalonia, Spain
ICO Girona Hospital Dr. Josep Trueta
Girona, Catalonia, Spain
Hospital Universitari Arnau de Vilanova
Lleida, Catalonia, Spain
Fundació Althaia, Xarxa Assistencial de Manresa
Manresa, Catalonia, Spain
Hospital General Universitario de Alicante
Alicante, Cominidad Valenciana, Spain
Complejo Hospitalario Universitario A Coruña
A Coruña, Galicia, Spain
Centro Oncologico de Galicia
A Coruña, Galicia, Spain
Complejo Hospitalario de Pontevedra
Pontevedra, Galicia, Spain
Hospital de Barbastro
Barbastro, Huesca, Spain
Hospital Clínico Universitario de Valencia
Valencia, Valencia, Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Barnadas A, Munoz M, Margeli M, Chacon JI, Cassinello J, Antolin S, Adrover E, Ramos M, Carrasco E, Jimeno MA, Ojeda B, Gonzalez X, Gonzalez S, Constenla M, Florian J, Miguel A, Llombart A, Lluch A, Ruiz-Borrego M, Colomer R, Del Barco S; GEICAM, Spanish Breast Cancer Group. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study. J Patient Rep Outcomes. 2019 Dec 21;3(1):72. doi: 10.1186/s41687-019-0161-y.
Related Links
Access external resources that provide additional context or updates about the study.
Spanish Breast Cancer Research Group (GEICAM) is a Spanish Breast Cancer Research Group
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Mabomet
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.